“Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance”, J of Skin, vol. 2, p. S57, Dec. 2018, doi: 10.25251/skin.2.supp.57.